All In Biotech

Drug Trial Radar · NCT02674152

Dose Finding Study of BI 836880 in Patients With Solid Tumors

A First-in Human Phase I, Non-randomised, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Repeated Intravenous Infusions in Patients With Solid Tumors.

Last checked: Nov 20, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

29

Actual

Start

Jan 5, 2016

Primary completion

Sep 12, 2018

Study completion Nov 4, 2020

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 4, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, non-randomized, uncontrolled, open-label, dose escalating study of BI 836880 administered intravenously. The eligible patient population will be patients with advanced solid tumours. At any time during the trial, it will not be permitted to escalate to a dose which does not fulfil the escalation with overdose control (EWOC) criterion

Conditions

  • Neoplasms

Interventions

  • BI 836880Drug

    BI 836880

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)Time frame: Up to 3 weeks after the first administration of trial medication.
  2. Number of Patients With Dose-limiting Toxicities (DLT) in the Maximum Tolerated Dose (MTD) PeriodTime frame: Up to 3 weeks after the first administration of trial medication.

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • INS Curie

    Paris, France

  • Universitätsklinikum Augsburg

    Augsburg, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.